CERo Therapeutics issues $437,500 convertible note to Keystone Capital Partners, 10% interest, due 2027

CERO THERAPEUTICS HOLDINGS, INC.

Issued to Keystone Capital Partners a convertible note with purchase price $350,000 and face value $437,500.
Note bears interest at 10% per annum, matures April 9, 2027, with up to $1,000,000 total borrowing capacity.
Conversion price is lesser of $0.05 or 80% of avg of 5 lowest intraday prices in 20 days prior to conversion.
Beneficial ownership limitation of 4.99% applies; issuance exempt from registration under Section 4(a)(2).

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.